Delivery Order SPE2DB24D2011-SPE2DB25FBRXQ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units, valued at $1,078.57 with a firm fixed price structure. This is a competitively awarded, non-set-aside contract with an ultimate completion date of October 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units, valued at $1,384.82 under a firm fixed price contract structure. This delivery order represents a competitive award with no set-aside designation and is scheduled for completion by September 17, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,813.90. This firm fixed-price delivery order is scheduled for completion by August 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive capability...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector units valued at $1,304.29 under a firm fixed price contract. This non-set-aside delivery order, which is scheduled for completion by September 5, 2025, will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,188.98 on July 22, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector units. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 23, 2025, and performance at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with DLA. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Xyosted 50 mg/0.5 ml auto-injector units with a ceiling value of $1,314.75 and a completion date of October 23, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award supporting federal medical procurement needs. The contract is performed at the awardee's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector pre-filled syringes valued at $1,716.22. This is a firm fixed price delivery order with an ultimate completion date of July 15, 2025, and represents a non-competitive set-aside award. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract, this delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,731.01. This firm fixed-price delivery order, which is due for completion by August 7, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award carries no set-aside designation, indicating it was competitively awarded. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $2,440.29 with a firm fixed price. This is a non-set-aside, competitively awarded delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector vials with a ceiling value of $1,074.75 and an ultimate completion date of August 12, 2025. This firm fixed-price delivery order is unclassified as a set-aside contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a...
- SPE2DB24D2011Indefinite Delivery Contract
- SPE2DB24D2011-SPE2DB25FBRXQDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $2,223.86 under a firm fixed price contract. The delivery order, which is a child contract under a larger vehicle, specifies a completion date of September 23, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania location. This award was not designated as a set-aside and was competitively awarded, reflecting AmerisourceBergen's capability to meet federal procurement standards through open competition. AmerisourceBergen Drug Corp holds a significant prime indefinite delivery contract with DLA Troop Support Medical (SPE2DX) valued at $999,999,999.00 through December 2026, which serves as the overarching vehicle supporting this delivery order. This comprehensive global pharmaceutical support contract enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The Xyosted auto-injector delivery reflects the company's role as a critical pharmaceutical vendor for the Defense Health Agency and other federal healthcare systems, providing specialized medical commodities across multiple therapeutic domains to support Department of Defense medical supply needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 9/22/25 |